TONIGHT THE POPE, PRESIDENT OF FRANCE AND CHERNOBYL
Posted on December 9, 2014 by keywestlou
*** begin quote ***
I have to vent. Price of prescription drugs again. I had to pick up a 30 day supply of the blood thinner prescribed for me. $121. And I have one of the best AARP supplemental drug programs!
There is no generic. The blood thinner came out in 2009.
It is the donut again. You who are over 65 will especially understand. I have been in the donut since June. I telephoned the insurance company last month. They said I could get out of the donut if I paid $4,000 odd dollars.
The drug companies and insurance companies continue to rip us off. Neither Obamacare nor anything else helps. The drug companies have continued to receive basically a free ride under Obama.
*** end quote ***
>The drug companies and insurance companies continue to rip us off.
You’re pointing at the wrong villain. It’s the Gooferment that allows Crony Capitalists to be protected from a true free market. AND, its FDA has several negative effects: (1) it raises the cost of getting a drug “approved”; (2) it adds decades to getting a drug to market; (3) it regularly denies approvals because it’s politically safer; and (4) it ignores that there are natural remedies and lifestyle changes that are more effective than drugs — but no one makes a profit on those.
>Neither Obamacare nor anything else helps.
Obamacare was written by the insurance companies. You expect that to change anything?
Medicare was camel’s nose of getting the Gooferment into healthcare.
And, it’s been more and more intrusive ever since.
We need Separation of Medicine and State!
>The drug companies have continued to receive basically a free ride under Obama.
Not just a free ride. They’ve actually INCREASED their political influence to Society’s detriment.
# – # – # – # – #
THE WALL STREET JOURNAL News Alert
FDA Advisers’ Financial Ties Not DisclosedThe Food and Drug Administration hasn’t disclosed numerous financial ties between medical-device makers and the doctors and other experts who review devices for the FDA, a Wall Street Journal analysis of corporate, state and federal data shows.
In panels evaluating devices involved in cardiology, orthopedics and gynecology from 2012 through 2014, a third of 122 members had received compensation–such as money, research grants or travel and food–from medical-device companies.
Nearly 10% of the FDA advisers received something of value from the specific company whose product they were evaluating.
# – # – # – # – #